Most of patients with localized prostate cancer will be treated in the future? | Opinion: No.
作者信息
Schulman Ariel A, Polascik Thomas J
机构信息
Division of Urology, Duke University Medical Center, Durham, NC, USA.
出版信息
Int Braz J Urol. 2017 Jul-Aug;43(4):584-587. doi: 10.1590/S1677-5538.IBJU.2017.04.03.
Abstract
摘要
相似文献
1
Most of patients with localized prostate cancer will be treated in the future? | Opinion: No.大多数局限性前列腺癌患者未来都会接受治疗吗？| 观点：不会。
Int Braz J Urol. 2017 Jul-Aug;43(4):584-587. doi: 10.1590/S1677-5538.IBJU.2017.04.03.
2
Most of patients with localized prostate cancer will be treated in the future? | Opinion: Yes.大多数局限性前列腺癌患者未来都会接受治疗吗？| 观点：是的。
Int Braz J Urol. 2017 Jul-Aug;43(4):579-583. doi: 10.1590/S1677-5538.IBJU.2017.04.02.
3
Prostate-specific antigen dynamics and prostate cancer diagnosis.前列腺特异性抗原动态变化与前列腺癌诊断
Eur Urol. 2009 Nov;56(5):761-2; discussion 763. doi: 10.1016/j.eururo.2009.07.048. Epub 2009 Aug 4.
4
[Prostate tumors].
Rev Prat. 2002 Jan 15;52(2):207-12.
5
[Early detection of prostatic carcinoma: Is PSA screening suitable?].[前列腺癌的早期检测：前列腺特异性抗原筛查是否合适？]
Dtsch Med Wochenschr. 2003 May 2;128(18):977.
6
Focal therapy meets prostate cancer.聚焦治疗与前列腺癌相遇。
Lancet. 2010 Sep 25;376(9746):1036-7. doi: 10.1016/S0140-6736(10)60594-6.
7
Prostate-specific antigen-based prostate cancer screening: Past and future.基于前列腺特异性抗原的前列腺癌筛查：过去与未来
Int J Urol. 2015 Jun;22(6):524-32. doi: 10.1111/iju.12750. Epub 2015 Apr 6.
8
Detecting and treating prostate cancer: a surgeon's perspective.
N Z Med J. 2012 Apr 20;125(1353):6-8.
9
Summaries for patients. Screening smarter, not harder, for prostate cancer.患者摘要。更明智而非更费力地筛查前列腺癌。
Ann Intern Med. 2013 Feb 5;158(3):I-30. doi: 10.7326/0003-4819-158-3-201302050-00001.
10
[Diagnosis and treatment of early-stage prostate carcinoma. Improved prognosis--fewer complications].[早期前列腺癌的诊断与治疗。预后改善——并发症减少]
MMW Fortschr Med. 2010 May 13;152(19):36.
本文引用的文献
1
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.多参数 MRI 和 TRUS 活检在前列腺癌（PROMIS）中的诊断准确性：一项配对验证性研究。
Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.
2
Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States.美国前列腺癌诊断时远处转移的增加。
JAMA Oncol. 2017 May 1;3(5):705-707. doi: 10.1001/jamaoncol.2016.5465.
3
High-intensity focused ultrasound for focal therapy: reality or pitfall?高强度聚焦超声用于局部治疗：现实还是陷阱？
Curr Opin Urol. 2017 Mar;27(2):138-148. doi: 10.1097/MOU.0000000000000372.
4
National Trends in Prostate Biopsy and Radical Prostatectomy Volumes Following the US Preventive Services Task Force Guidelines Against Prostate-Specific Antigen Screening.美国预防服务工作组指南禁止前列腺特异性抗原筛查后，前列腺活检和根治性前列腺切除术数量的全国趋势。
JAMA Surg. 2017 Feb 1;152(2):192-198. doi: 10.1001/jamasurg.2016.3987.
5
Active surveillance for intermediate-risk prostate cancer.对中危前列腺癌的主动监测
Prostate Cancer Prostatic Dis. 2017 Mar;20(1):1-6. doi: 10.1038/pcan.2016.51. Epub 2016 Nov 1.
6
Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer.前列腺健康指数可改善侵袭性前列腺癌的多变量风险预测。
BJU Int. 2017 Jul;120(1):61-68. doi: 10.1111/bju.13676. Epub 2016 Nov 22.
7
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer.局限性前列腺癌监测、手术或放疗 10 年后的结果。
N Engl J Med. 2016 Oct 13;375(15):1415-1424. doi: 10.1056/NEJMoa1606220. Epub 2016 Sep 14.
8
Targeted Anterior Gland Focal Therapy-a Novel Treatment Option for a Better Defined Disease.靶向性前列腺前叶聚焦治疗——一种针对更明确疾病的新型治疗选择。
Curr Urol Rep. 2016 Oct;17(10):69. doi: 10.1007/s11934-016-0628-9.
9
Reevaluating PSA Testing Rates in the PLCO Trial.重新评估前列腺、肺、结直肠癌和卵巢癌筛查试验（PLCO）中的前列腺特异性抗原（PSA）检测率
N Engl J Med. 2016 May 5;374(18):1795-6. doi: 10.1056/NEJMc1515131.
10
Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.与 USPSTF 筛查建议相关的前列腺癌发病率和 PSA 检测模式。
JAMA. 2015 Nov 17;314(19):2054-61. doi: 10.1001/jama.2015.14905.
Zotero 插件